Stock listing
NASDAQ:NVCR NovoCure Limited Stock
Home listing (NASDAQ) of NovoCure Limited
Follow NovoCure Limited into a list and get an email when it puts out news.
Share price · NASDAQ:NVCR
$10.71 USD -0.02 (-0.2%)
Close on Nov 20, 2026
- Day range
- $10.61 – $11.06 USDNov 20, 2026
- Volume
- 1.64M sharesNov 20, 2026
- Market cap
- $1.25B USDAt the close on Nov 20, 2026 · price × 116.4M shares outstanding
- 52-week range
- $9.82 – $21.45 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $21.77M USDMedian day 1.29M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:NVCR · Home | $10.71 USD | -0.02 (-0.2%) | 1,639,199 | $10.61 | $11.06 | $10.61 | $10.73 | Close on Nov 20, 2026 |
| Frankfurt:038 | €9.70 EUR | +0.134 (+1.4%) | — | €9.406 | €9.70 | €9.406 | €9.566 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:NVCR · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $10.71 | -0.02 | -0.2% | $10.61 | $11.06 | $10.61 | 1,639,199 | |
| $10.73 | -0.41 | -3.7% | $11.16 | $11.35 | $10.69 | 1,409,845 | |
| $11.14 | -0.16 | -1.4% | $11.31 | $11.51 | $11.05 | 1,442,838 | |
| $11.30 | -0.53 | -4.5% | $11.61 | $11.72 | $11.25 | 2,438,113 | |
| $11.83 | +0.11 | +0.9% | $11.70 | $11.88 | $11.44 | 1,051,730 | |
| $11.72 | -0.27 | -2.3% | $11.84 | $12.11 | $11.63 | 1,246,669 | |
| $11.99 | +0.18 | +1.5% | $12.01 | $12.41 | $11.75 | 1,533,011 | |
| $11.81 | -0.72 | -5.7% | $12.68 | $12.95 | $11.56 | 1,928,993 | |
| $12.53 | -0.75 | -5.6% | $12.99 | $13.23 | $12.25 | 2,379,205 | |
| $13.28 | -0.27 | -2.0% | $13.52 | $13.59 | $13.06 | 1,143,981 | |
| $13.55 | -1.06 | -7.3% | $14.61 | $14.68 | $13.49 | 1,695,043 | |
| $14.61 | +1.18 | +8.8% | $14.00 | $14.94 | $13.92 | 1,647,780 | |
| $13.43 | +0.22 | +1.7% | $13.30 | $13.56 | $13.21 | 1,652,338 | |
| $13.21 | +0.06 | +0.5% | $13.33 | $13.67 | $13.09 | 1,647,264 | |
| $13.15 | +0.04 | +0.3% | $12.81 | $13.26 | $12.53 | 1,974,507 | |
| $13.11 | -1.06 | -7.5% | $12.90 | $13.85 | $11.85 | 5,953,164 | |
| $14.17 | -0.45 | -3.1% | $14.42 | $14.64 | $13.85 | 2,383,079 | |
| $14.62 | +0.22 | +1.5% | $14.40 | $14.74 | $14.11 | 2,147,157 | |
| $14.40 | -0.28 | -1.9% | $14.47 | $14.90 | $14.20 | 1,166,269 | |
| $14.68 | -0.42 | -2.8% | $14.85 | $14.97 | $14.53 | 1,125,100 | |
| $15.10 | -0.49 | -3.1% | $15.55 | $15.66 | $14.94 | 1,059,800 | |
| $15.59 | -0.12 | -0.8% | $15.60 | $16.09 | $15.43 | 2,599,200 | |
| $15.71 | +0.82 | +5.5% | $14.98 | $15.82 | $14.91 | 1,737,800 | |
| $14.89 | +0.82 | +5.8% | $14.14 | $15.00 | $14.14 | 2,225,000 | |
| $14.07 | -0.34 | -2.4% | $14.41 | $14.41 | $13.88 | 1,287,600 | |
| $14.41 | +0.57 | +4.1% | $13.85 | $14.46 | $13.84 | 1,810,600 | |
| $13.84 | -0.46 | -3.2% | $14.15 | $14.26 | $13.76 | 1,186,000 | |
| $14.30 | -0.42 | -2.9% | $14.66 | $14.75 | $14.29 | 772,600 | |
| $14.72 | +0.14 | +1.0% | $14.54 | $14.76 | $14.26 | 782,000 | |
| $14.58 | +0.36 | +2.5% | $14.17 | $14.78 | $14.14 | 1,022,300 | |
| $14.22 | -0.44 | -3.0% | $14.59 | $14.59 | $13.82 | 2,956,800 | |
| $14.66 | -0.31 | -2.1% | $14.84 | $15.12 | $14.59 | 3,513,300 | |
| $14.97 | -0.23 | -1.5% | $15.27 | $15.88 | $14.90 | 1,763,300 | |
| $15.20 | +0.26 | +1.7% | $14.83 | $15.30 | $14.56 | 1,784,600 | |
| $14.94 | -0.98 | -6.2% | $16.24 | $16.24 | $14.92 | 1,695,100 | |
| $15.92 | -0.03 | -0.2% | $15.81 | $16.44 | $15.77 | 1,208,100 | |
| $15.95 | -0.04 | -0.3% | $16.01 | $16.10 | $15.73 | 1,876,600 | |
| $15.99 | +0.16 | +1.0% | $15.87 | $16.07 | $15.64 | 728,500 | |
| $15.83 | -0.01 | -0.1% | $15.68 | $15.90 | $15.20 | 896,000 | |
| $15.84 | -0.36 | -2.2% | $16.20 | $16.27 | $15.82 | 1,028,000 | |
| $16.20 | -0.05 | -0.3% | $16.43 | $16.43 | $15.73 | 1,142,600 | |
| $16.25 | -0.42 | -2.5% | $16.53 | $16.75 | $15.97 | 777,700 | |
| $16.67 | +0.14 | +0.8% | $16.70 | $16.79 | $16.54 | 1,044,600 | |
| $16.53 | -0.16 | -1.0% | $16.87 | $16.87 | $16.37 | 633,500 | |
| $16.69 | -0.03 | -0.2% | $16.70 | $16.87 | $16.53 | 1,152,700 | |
| $16.72 | +0.50 | +3.1% | $16.58 | $16.99 | $16.13 | 1,482,600 | |
| $16.22 | +0.07 | +0.4% | $16.18 | $16.55 | $16.01 | 1,639,300 | |
| $16.15 | -0.07 | -0.4% | $16.13 | $16.66 | $15.96 | 914,800 | |
| $16.22 | +0.71 | +4.6% | $15.49 | $16.25 | $15.29 | 1,049,300 | |
| $15.51 | +0.16 | +1.0% | $15.50 | $16.00 | $15.35 | 1,127,200 | |
| $15.35 | -0.28 | -1.8% | $15.26 | $16.07 | $15.10 | 1,385,200 | |
| $15.63 | -1.22 | -7.2% | $16.56 | $16.65 | $15.60 | 995,500 | |
| $16.85 | -1.09 | -6.1% | $17.64 | $17.78 | $16.57 | 1,459,700 | |
| $17.94 | +0.30 | +1.7% | $17.53 | $18.02 | $17.47 | 732,000 | |
| $17.64 | -0.19 | -1.1% | $17.94 | $18.05 | $17.42 | 613,400 | |
| $17.83 | +0.45 | +2.6% | $17.88 | $18.59 | $17.50 | 1,324,000 | |
| $17.38 | -0.27 | -1.5% | $17.36 | $17.88 | $17.29 | 800,300 | |
| $17.65 | -0.17 | -1.0% | $17.55 | $17.97 | $17.39 | 914,800 | |
| $17.82 | -0.17 | -0.9% | $17.99 | $18.16 | $17.42 | 855,600 | |
| $17.99 | +0.10 | +0.6% | $17.92 | $18.21 | $17.48 | 763,400 | |
| $17.89 | +0.27 | +1.5% | $17.43 | $17.97 | $17.15 | 1,270,900 | |
| $17.62 | +0.86 | +5.1% | $16.98 | $17.64 | $16.92 | 902,900 | |
| $16.76 | -0.34 | -2.0% | $17.02 | $17.06 | $16.33 | 1,607,200 | |
| $17.10 | -0.67 | -3.8% | $17.75 | $17.83 | $17.01 | 1,403,800 | |
| $17.77 | -0.43 | -2.4% | $18.12 | $18.61 | $17.48 | 955,700 |
- Ticker
- NASDAQ:NVCR
- Asset type
- Stock
- Sector
- Health care
- Industry
- Medical devices & supplies
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 19, 2026
Novocure Announces Upcoming Investor Events
Latest earnings call · Oct 29, 2026
NovoCure (NASDAQ:NVCR) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Oct 29, 2026
Q3 2026 Earnings Presentation
Earnings · 15 slides
Latest news
Novocure Announces Upcoming Investor Events
Nov 19, 2026
Closed $10.71 (-0.2%) on Nov 20, 2026
JAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields for Pancreatic Cancer
Nov 13, 2026
Closed $11.83 (+0.9%) on Nov 13, 2026
Novocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya® for Brain Metastases from Non-Small Cell Lung Cancer
Nov 9, 2026
Closed $12.53 (-5.6%) on Nov 9, 2026
Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance
Oct 29, 2026
Closed $13.11 (-7.5%) on Oct 29, 2026
Novocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply Agreement
Oct 28, 2026
Closed $14.17 (-3.1%) on Oct 28, 2026
Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer
Oct 1, 2026
Closed $15.92 (-0.2%) on Oct 1, 2026
Novocure to Report Third Quarter 2026 Financial Results
Oct 1, 2026
Closed $15.92 (-0.2%) on Oct 1, 2026
Novocure Reports Second Quarter 2026 Financial Results
Jul 23, 2026
Closed $19.99 (+28.4%) on Jul 23, 2026
Novocure to Report Second Quarter 2026 Financial Results
Jul 1, 2026
Closed $15.78 (+4.2%) on Jul 1, 2026
Novocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer
Jun 30, 2026
Closed $15.15 (-2.1%) on Jun 30, 2026
NovoCure Limited on 6ix
- Sector
- Health care
- Industry
- Medical devices & supplies
- News releases
- 23 in the last 12 months · 192 in all · newest Nov 19, 2026 · oldest 2020
- Calls
- 25 calls with a replay · 25 with a transcript · latest Oct 29, 2026
- Decks
- 42 decks · latest Oct 29, 2026
Where NovoCure Limited is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:NVCR · Home listing · This page | NASDAQ | United States | USD |
| gettex:038 | gettex | Germany | EUR |
| LS Exchange:A140ML | LS Exchange | Germany | EUR |
| BOATS:NVCR | BOATS | United States | USD |
| Lang & Schwarz:A140ML | Lang & Schwarz | Germany | EUR |
| B3:N2VC34 | B3 | Brazil | BRL |
| Tradegate:038 | Tradegate | Germany | EUR |
| BMV:NVCRN | BMV | Mexico | MXN |
| BIVA:NVCRN | BIVA | Mexico | MXN |
| Frankfurt:038 | Frankfurt | Germany | EUR |
| Dusseldorf:038 | Dusseldorf | Germany | EUR |
| Munich:038 | Munich | Germany | EUR |
| Stuttgart:038 | Stuttgart | Germany | EUR |
| BSESOF:038 | BSESOF | Bulgaria | EUR |
Valuation
EV/sales 1.6× against a median of 3.4×: 4th lowest of 11 Medical devices & supplies companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.18B USD
- P/E
- Loss
- EV/sales
- 1.6×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 3.6×
- Gross margin
- 77.0%
- Operating margin
- −17.2%
- Net margin
- −16.8%
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 1.31
Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| NovoCure Limited · NASDAQ:NVCR | US$1.25B | US$1.18B | n/a | 1.6× | n/a | 3.6× | −16.8% | 0.1× | 1.31 |
| PROCEPT BioRobotics Corporation · NASDAQ:PRCT | US$1.42B | US$1.25B | n/a | 3.6× | n/a | 4.3× | −32.6% | 0.2× | 0.89 |
| CONMED Corporation · NYSE:CNMD | US$1.39B | US$2.16B | 29.6× | 1.6× | 18.1× | 1.3× | 3.4% | 0.8× | 0.77 |
| Cofoe Medical Technology Co., Ltd. Class A · SZSE:301087 | US$1.36B | US$930.0M | 21.9× | 1.5× | n/a | 1.7× | 10.0% | 0.0× | n/a |
| Butterfly Network, Inc. · NYSE:BFLY | US$1.33B | US$1.21B | n/a | 9.8× | n/a | 7.2× | −43.6% | 0.0× | 2.86 |
| Beijing Balance Medical Technology Co. Ltd. Class A · SSE:688198 | US$1.27B | US$1.26B | 47.8× | 12.8× | n/a | 7.2× | 27.2% | 0.1× | n/a |
| Shanghai MicroPort EP Medtech Co., Ltd. Class A · SSE:688351 | US$1.24B | US$1.05B | 144× | 12.8× | n/a | 4.5× | 10.4% | 0.0× | n/a |
| Sonoscape Medical Corp. Class A · SZSE:300633 | US$1.23B | US$1.11B | 47.0× | 3.0× | n/a | 2.7× | 7.2% | 0.1× | n/a |
| Tandem Diabetes Care, Inc. · NASDAQ:TNDM | US$1.22B | US$1.38B | n/a | 1.3× | n/a | 9.0× | −4.6% | 4.5× | 0.97 |
| STAAR Surgical Company · NASDAQ:STAA | US$1.22B | US$1.04B | 2,294× | 3.2× | 120× | 3.2× | 0.2% | 0.1× | 0.45 |
| Eyebright Medical Technology (Beijing) Co., Ltd. Class A · SSE:688050 | US$1.18B | US$1.21B | 32.6× | 4.5× | n/a | 2.6× | 13.5% | 0.3× | n/a |
| Median of the others | US$1.26B | US$1.21B | 47.0× | 3.4× | 69.2× | 3.8× | 5.3% | 0.1× | 0.89 |
Forecasts
3 strong buy · 1 buy · 3 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 26.14 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.05 · 6 analysts
- Revenue, year to Dec 2026
- 740.2M · 6 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Frank Leonard | Chief Executive Officer |
| Christoph Brackmann | Chief Financial Officer |
| Mukund Paravasthu | Chief Operating Officer |
| Michael Puri | Chief Human Resources Officer |
| Uri Weinberg | Chief Medical & Innovation Officer |
| William F. Doyle | Executive Chairman |
Board
| Director | Role |
|---|---|
| William F. Doyle | Executive Chairman |
| Allyson J. Ocean | |
| Asaf Danziger | |
| David T. Hung | |
| Jeryl Hilleman | |
| Kinyip Gabriel Leung | |
| Kristin Stafford | |
| Martin J. Madden | |
| William A. Vernon |
Events
Calls
| Call | When | Status |
|---|---|---|
| NovoCure (NASDAQ:NVCR) Q3 2026 Earnings Call | Thu, Oct 29, 2026 · 8:00 AM ET | Replay |
| NovoCure (NASDAQ:NVCR) Q2 2026 Earnings Call | Thu, Jul 23, 2026 · 8:00 AM ET | Replay |
| NovoCure (NASDAQ:NVCR) Q1 2026 Earnings Call | Thu, Apr 30, 2026 · 8:00 AM ET | Replay |
| NovoCure (NASDAQ:NVCR) Q4 2025 Earnings Call | Thu, Feb 26, 2026 · 8:00 AM ET | Replay |
| NovoCure (NASDAQ:NVCR) Q3 2025 Earnings Call | Thu, Oct 30, 2025 · 8:00 AM ET | Replay |
| NovoCure (NASDAQ:NVCR) Q2 2025 Earnings Call | Thu, Jul 24, 2025 · 8:00 AM ET | Replay |
| NovoCure (NASDAQ:NVCR) Q1 2025 Earnings Call | Thu, Apr 24, 2025 · 8:00 AM ET | Replay |
| NovoCure (NASDAQ:NVCR) Q4 2024 Earnings Call | Thu, Feb 27, 2025 · 8:00 AM ET | Replay |
| NovoCure (NASDAQ:NVCR) Q3 2024 Earnings Call | Wed, Oct 30, 2024 · 8:00 AM ET | Replay |
| NovoCure (NASDAQ:NVCR) Q2 2024 Earnings Call | Thu, Jul 25, 2024 · 8:00 AM ET | Replay |
All 25 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Oct 29, 2026 · Before open | −7.5% |
| Q2 2026 | Jul 23, 2026 · Before open | +28.4% |
| Q1 2026 | Apr 30, 2026 · Before open | +27.5% |
| Q4 2025 | Feb 26, 2026 | −8.8% |
| Q3 2025 | Oct 30, 2025 · Before open | −4.9% |
| Q2 2025 | Jul 24, 2025 · Before open | −24.1% |
| Q1 2025 | Apr 24, 2025 · Before open | +4.4% |
| Q4 2024 | Feb 27, 2025 | −13.2% |
| Q3 2024 | Oct 30, 2024 · Before open | +0.6% |
| Q2 2024 | Jul 25, 2024 · Before open | −0.8% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 2, 2024 · Before open | +11.4% |
| Q4 2023 | Feb 22, 2024 · Before open | −2.4% |
| Q3 2023 | Oct 26, 2023 · Before open | −7.5% |
| Q2 2023 | Jul 27, 2023 · Before open | −15.9% |
| Q1 2023 | May 4, 2023 · Before open | +1.2% |
| Q4 2022 | Feb 23, 2023 · Before open | −4.5% |
| Q3 2022 | Oct 27, 2022 · Before open | +0.2% |
| Q2 2022 | Jul 28, 2022 · Before open | −5.0% |
| Q1 2022 | Apr 28, 2022 · Before open | +0.3% |
| Q4 2021 | Feb 24, 2022 · Before open | +6.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 15 slides | Oct 29, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 12 slides | Jul 23, 2026 |
| Investor Presentation (July 2026) | Investor deck | 15 slides | July 2026 |
| Q1 2026 Earnings Presentation | Earnings | 12 slides | Apr 30, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 12 slides | Feb 26, 2026 |
| Q3 2025 Earnings Presentation | Earnings | 11 slides | Oct 30, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 13 slides | Jul 24, 2025 |
| Technical Presentation (June 2025) | Technical | 26 slides | Jun 2, 2025 |
| Investor Day (June 2025) | Investor day | 43 slides | Jun 2, 2025 |
| Investor Presentation (October 2024) | Investor deck | 22 slides | October 2024 |
All 42 decks
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 655.4M | 605.2M | 509.3M | 537.8M | 535.0M | 494.4M | 351.3M | 248.1M | 177.0M | 82.9M |
| Cost of revenue | 166.9M | 137.2M | 128.3M | 114.9M | 114.9M | 106.5M | 88.6M | 80.0M | 55.6M | 39.9M |
| Gross profit | 488.5M | 468.0M | 381.1M | 423.0M | 420.2M | 387.9M | 262.7M | 168.0M | 121.4M | 36.6M |
| Research and development | 224.5M | 209.6M | 223.1M | 206.1M | 201.3M | 132.0M | 79.0M | 50.6M | 38.1M | 41.5M |
| Operating income | -153.8M | -170.5M | -232.9M | -89.5M | -44.3M | 30.4M | -914.0K | -33.7M | -39.3M | -115.3M |
| Depreciation and amortization | 14.7M | 11.2M | 11.0M | 10.6M | 10.3M | 9.15M | 8.46M | 9.01M | 7.68M | 5.65M |
| EBITDA | -139.2M | -159.3M | -221.9M | -78.9M | -34.1M | 39.6M | 7.55M | -24.7M | -31.7M | -109.7M |
| Interest expense | 22.2M | 11.7M | 4.91M | 8.11M | 8.84M | 18.1M | 14.6M | 16.9M | 11.7M | 7.32M |
| Income before tax | -136.3M | -131.2M | -191.7M | -81.8M | -52.1M | 18.1M | -8.82M | -45.9M | -48.5M | -121.5M |
| Income tax | -23.0K | 37.5M | 15.3M | 10.7M | 6.28M | -1.71M | -1.59M | 17.6M | 13.2M | 10.4M |
| Net income | -136.2M | -168.6M | -207.0M | -92.5M | -58.4M | 19.8M | -7.23M | -63.6M | -61.7M | -131.8M |
| Earnings per share, basic | -1.22 | -1.56 | -1.95 | -0.88 | -0.56 | 0.20 | -0.07 | -0.69 | -0.70 | -1.54 |
| Earnings per share, diluted | -1.22 | -1.56 | -1.95 | -0.88 | -0.56 | 0.18 | -0.07 | -0.69 | -0.70 | -1.54 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 93.5M | 163.8M | 240.8M | 115.3M | 208.8M | 234.7M | 177.3M | 140.6M | 78.6M | 99.8M |
| Receivables | 89.4M | 74.2M | 61.2M | 86.3M | 93.6M | 96.7M | 58.9M | 36.5M | 29.6M | 6.34M |
| Inventory | 41.1M | 35.1M | 38.2M | 29.4M | 24.4M | 27.4M | 23.7M | 22.6M | 22.0M | 25.5M |
| Current assets | 646.7M | 1.11B | 1.03B | 1.11B | 1.07B | 999.4M | 439.9M | 321.4M | 245.1M | 261.9M |
| Property, plant and equipment | 77.6M | 77.7M | 51.5M | 32.7M | 22.7M | 11.4M | 9.34M | 8.44M | 9.03M | 9.81M |
| Total assets | 804.3M | 1.24B | 1.15B | 1.19B | 1.14B | 1.05B | 479.4M | 339.8M | 265.3M | 282.1M |
| Current liabilities | 223.2M | 756.4M | 179.1M | 158.8M | 142.6M | 113.6M | 86.3M | 64.6M | 50.2M | 36.9M |
| Long-term debt | 195.0M | 97.3M | 568.8M | 565.5M | 562.2M | 429.9M | 149.4M | 149.3M | 97.3M | 96.2M |
| Total debt | 195.0M | 97.3M | 568.8M | 565.5M | 562.2M | 429.9M | 149.4M | 125.0K | 160.0K | 263.0K |
| Total liabilities | 463.9M | 880.6M | 783.6M | 750.5M | 729.0M | 575.5M | 261.7M | 227.5M | 151.7M | 139.7M |
| Shareholders' equity | 340.5M | 360.2M | 362.5M | 441.2M | 410.5M | 476.5M | 217.8M | 112.3M | 113.6M | 142.3M |
| Shares outstanding | 112.5M | 108.5M | 107.1M | 105.0M | 104.0M | 102.3M | 99.5M | 93.3M | 89.5M | 87.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -49.0M | -26.4M | -73.3M | 30.8M | 82.8M | 99.1M | 26.6M | -1.86M | -33.1M | -107.6M |
| Capital spending | -26.6M | -42.9M | -27.1M | -21.4M | -24.2M | -15.0M | -10.5M | -6.71M | -7.37M | -5.67M |
| Free cash flow | -75.7M | -69.2M | -100.4M | 9.43M | 58.6M | 84.2M | 16.1M | -8.58M | -40.5M | -113.3M |
| Cash from investing | 437.3M | -140.2M | 184.1M | -140.0M | -144.8M | -472.8M | -51.7M | -5.49M | 8.63M | 13.0M |
| Cash from financing | -451.3M | 90.3M | 15.8M | 15.5M | 25.7M | 440.2M | 61.7M | 69.4M | 5.17M | 75.1M |
| Dividends paid | 0 | 0 | ||||||||
| Change in cash | -62.7M | -76.5M | 126.7M | -93.8M | -36.6M | 66.8M | 36.7M | 62.0M | -19.3M | -19.6M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 9, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Nov 9, 2026 | Other filings | SEC |
| 8-K · Current report | Nov 9, 2026 | Current report | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Oct 29, 2026 | Offer document | SEC |
| 8-K · Current report | Oct 29, 2026 | Results | SEC |
| 10-Q · Quarterly report | Oct 29, 2026 | Quarterly report | SEC |
| 8-K · Current report | Oct 1, 2026 | Current report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Sep 9, 2026 | Management or board change | SEC |
| 8-K · Current report | Sep 1, 2026 | Current report | SEC |
| 144 · Notice of proposed sale | Jul 23, 2026 | Other filings | SEC |
| 8-K · Current report | Jul 23, 2026 | Results | SEC |
| 10-Q · Quarterly report | Jul 23, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 30, 2026 | Current report | SEC |
| 8-K · Current report | Jun 18, 2026 | Current report | SEC |
| 8-K · Current report | Jun 5, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 4, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| DEFA14A · Additional proxy material | May 21, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 8, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Apr 30, 2026 | Results | SEC |
| 10-Q · Quarterly report | Apr 30, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Apr 28, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 28, 2026 | Big-stake notice | SEC |
| 8-K/A · Current report, amended | Apr 24, 2026 | Management or board change | SEC |
| DEFA14A · Additional proxy material | Apr 20, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 20, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 9, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Mar 26, 2026 | Current report | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 3, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 27, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 27, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Feb 26, 2026 | Offer document | SEC |
| 10-K · Annual report | Feb 26, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 26, 2026 | Results | SEC |
| 8-K · Current report | Feb 24, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 11, 2026 | Current report | SEC |
| 8-K · Current report | Feb 5, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 12, 2026 | Results | SEC |
| 5 · Annual statement of ownership | Jan 8, 2026 | Insider trade | SEC |
| 5 · Annual statement of ownership | Jan 8, 2026 | Insider trade | SEC |
| 5 · Annual statement of ownership | Jan 8, 2026 | Insider trade | SEC |
| 8-K · Current report | Dec 1, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 7, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 4, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Oct 30, 2025 | Quarterly report | SEC |
| 8-K · Current report | Oct 30, 2025 | Results | SEC |
| 8-K · Current report | Sep 15, 2025 | Current report | SEC |
| 4 · Change in ownership | Sep 8, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 28, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 13, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 5, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 30, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 24, 2025 | Results | SEC |
| 10-Q · Quarterly report | Jul 24, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 7, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| S-8 POS | Jun 30, 2025 | Offer document | SEC |
| S-8 POS | Jun 30, 2025 | Offer document | SEC |
| S-8 POS | Jun 30, 2025 | Offer document | SEC |
| S-8 POS | Jun 30, 2025 | Offer document | SEC |
| S-8 POS | Jun 30, 2025 | Offer document | SEC |
| S-8 POS | Jun 30, 2025 | Offer document | SEC |
| S-8 POS | Jun 30, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 6, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 2, 2025 | Other filings | SEC |
| 8-K · Current report | Jun 2, 2025 | Current report | SEC |
| 4 · Change in ownership | May 5, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 5, 2025 | Other filings | SEC |
| 8-K · Current report | Apr 24, 2025 | Results | SEC |
| 10-Q · Quarterly report | Apr 24, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 23, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Apr 22, 2025 | Current report | SEC |
| DEFA14A · Additional proxy material | Apr 21, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 21, 2025 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 1, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Mar 3, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Mar 3, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Mar 3, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Mar 3, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Mar 3, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Mar 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 3, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 3, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 3, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 3, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 3, 2025 | Other filings | SEC |
| 4 · Change in ownership | Mar 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 28, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 28, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 28, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 28, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 28, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 27, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 27, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 27, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 27, 2025 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Feb 27, 2025 | Offer document | SEC |
| 8-K · Current report | Feb 27, 2025 | Results | SEC |
| 10-K · Annual report | Feb 27, 2025 | Annual report | SEC |
| 4 · Change in ownership | Jan 15, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 13, 2025 | Other filings | SEC |
| 8-K · Current report | Jan 13, 2025 | Results | SEC |
| 3 · Initial statement of ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 2, 2025 | Other filings | SEC |
| 8-K/A · Current report, amended | Dec 16, 2024 | Management or board change | SEC |
| 8-K · Current report | Dec 2, 2024 | Current report | SEC |
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from NovoCure Limited’s releases
- Common shares
- 116,445,840
- Fully diluted
- 116,445,840
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 116,445,840 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 116,445,840 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Louis J Lavigne Jr Other companies: Alector, Inc. (Director · Since at least Feb 6, 2019); DocuSign, Inc. (Director · Apr 26, 2018 – Jun 17, 2019 · Past); Zynga Inc (Director · Apr 23, 2015 – May 23, 2022 · Past); Depomed Inc (Director · Jul 6, 2013 – May 8, 2018 · Past); Accuray Incorporated (Director · Sep 4, 2009 – Nov 30, 2020 · Past); BMC Software Inc (Director · Aug 22, 2006 – Sep 10, 2013 · Past); Kyphon Inc (Director · Jul 31, 2006 – Nov 2, 2007 · Past); Arena Pharmaceuticals Inc (Director · Jul 28, 2006 – Jul 28, 2006 · Past); Equinix, Inc. (Director · Jun 8, 2006 – Jun 8, 2006 · Past) | Director · Oct 1, 2015 – May 31, 2017 · Past |
| Robert J Mylod Jr Other companies: Bending Spoons S.p.A. (Director · Since at least Jul 1, 2026); Vroom, Inc. (Director · Since at least Jun 8, 2020); Booking Holdings Inc. Common Stock (Director · Since at least Feb 28, 2006); Dropbox, Inc. (Director · Mar 22, 2018 – May 20, 2021 · Past); Redfin Corp (Director · Jul 27, 2017 – Jun 12, 2022 · Past); Autoweb Inc (Director · Oct 1, 2015 – Jun 20, 2016 · Past) | Director · Oct 1, 2015 – May 4, 2016 · Past |
| Jeryl Jeri Hilleman Other companies: Omada Health, Inc. (Director · Since at least Jun 5, 2025); SI-BONE, Inc. (Director · Since at least Jun 13, 2022); Hillevax Inc (Director · Since at least Apr 28, 2022); Cutera Inc (Director · Jul 12, 2024 – Oct 24, 2024 · Past); Minerva Neurosciences, Inc (Director · Jun 10, 2022 – Sep 27, 2023 · Past) | Director · Since at least Jun 8, 2022 |
| Sherilyn McCoy Other companies: Kimberly-Clark Corporation (Director · Since at least Sep 12, 2018); Stryker Corporation (Lead Independent Director · Since at least May 2, 2018); Certara, Inc. (Director · Dec 11, 2020 – May 18, 2021 · Past); Avon Products Inc (CEO, Director · Apr 23, 2012 – Apr 23, 2017 · Past); Johnson & Johnson (Member, Executive Committee · Jan 2, 2008 – Feb 9, 2012 · Past) | Director · May 31, 2018 – Jun 9, 2021 · Past |
| Gabriel Leung Other companies: Pernix Therapeutics Holdings Inc (Director · Nov 21, 2016 – May 22, 2018 · Past); Delcath Systems, Inc. (Director · Mar 30, 2011 – Jul 7, 2014 · Past); Albany Molecular Research Inc (Director · Nov 2, 2010 – Mar 2, 2015 · Past); Osi Pharmaceuticals Inc (EVP & Pres. Pharma. Business · Jun 13, 2006 – Jun 7, 2010 · Past) | Director · Since at least Oct 1, 2015 |
| W. Anthony Vernon Other companies: Nuvation Bio Inc. (Director · Since at least Feb 10, 2021); McCormick & Company, Incorporated (Director · Since at least Mar 15, 2018); Intersect ENT Inc (Director · Jun 5, 2018 – Jun 4, 2020 · Past) | Director · Since at least May 31, 2017 |
| Kristin Stafford Other companies: Theravance Biopharma, Inc. (Chief Financial Officer · Since at least Nov 4, 2026); Zymeworks Inc. (Chief Financial Officer · Since at least Apr 1, 2026) | Director · Since at least Mar 28, 2023 |
| Timothy J Scannell Other companies: Insulet Corporation (Director · Since at least May 20, 2026); Masimo Corporation (Director · Since at least Apr 29, 2026) | Director · Since at least Jun 2, 2026 |
| David Hung Other companies: Nuvation Bio Inc. (PRESIDENT AND CEO, Director · Since at least Apr 4, 2025) | Director · Since at least Jun 3, 2025 |
| Ely Benaim Other companies: Opus Genetics, Inc. (Chief Medical Officer · Feb 2, 2015 – Feb 28, 2019 · Past) | Chief Medical Officer · Jul 24, 2019 – Jan 6, 2023 · Past |
All 33 people
| Person | Seat |
|---|---|
| Martin J. Madden Other companies: Microbot Medical Inc. (Director · Since at least Oct 23, 2019) | Director · Since at least May 21, 2019 |
| Wilhelmus Cm Groenhuysen Other companies: OptiNose (Director · Oct 12, 2017 – May 21, 2025 · Past) | Chief Operating Officer · Oct 1, 2015 – Jun 28, 2024 · Past |
| William Doyle Other companies: ProKidney Corp. (Lead Independent Director · Since at least Nov 19, 2026) | Executive Chairman · Since at least Dec 22, 2025 |
| Allyson J. Ocean | Director · Since at least Feb 22, 2023 |
| Arye Barak Ben | General Counsel · Since at least Apr 14, 2022 |
| Asaf Danziger | Director · Since at least Oct 1, 2015 |
| Ashley Cordova | Former Chief Executive Officer · Since at least Sep 1, 2020 |
| Charles G Phillips III | Director · Oct 1, 2015 – Dec 2, 2019 · Past |
| Christoph Brackmann | Chief Financial Officer · Since at least Jan 1, 2025 |
| Eilon D Kirson | Chief Science Officer · Oct 1, 2015 – Feb 27, 2019 · Past |
| Frank Leonard | Chief Executive Officer · Since at least Sep 1, 2020 |
| Kinyip Gabriel Leung | Director · Since at least Nov 5, 2026 |
| Michael J Ambrogi | Chief Operating Officer · Oct 1, 2015 – Jul 21, 2020 · Past |
| Michael Puri | Chief Human Resources Officer · Since at least Nov 5, 2026 |
| Michal Nath Puri | Chief Human Resources Officer · Since at least Oct 25, 2023 |
| Mukund Paravasthu | Chief Operating Officer · Since at least Oct 1, 2024 |
| Nicolas Leupin | Former Chief Medical Officer · Since at least Jan 2, 2024 |
| Pritesh Shah | Chief Growth Officer · Jul 1, 2018 – Nov 7, 2023 · Past |
| Timothy J Langloss | Director · Oct 1, 2015 – May 5, 2016 · Past |
| Uri Weinberg | Chief Medical & Innovation Officer · Since at least Apr 30, 2020 |
| William A. Vernon | Director · Since at least Feb 26, 2026 |
| William Patrick Burke | Chief Human Resources Officer · Sep 1, 2021 – Jun 30, 2023 · Past |
| Yoram Palti | Chief Technology Officer, Director · Apr 18, 2016 – Aug 28, 2018 · Past |
Log in to ask 6ix AI your own questions about NovoCure Limited.